PL3360864T3 - Związek pirymidynowy - Google Patents

Związek pirymidynowy

Info

Publication number
PL3360864T3
PL3360864T3 PL16853686T PL16853686T PL3360864T3 PL 3360864 T3 PL3360864 T3 PL 3360864T3 PL 16853686 T PL16853686 T PL 16853686T PL 16853686 T PL16853686 T PL 16853686T PL 3360864 T3 PL3360864 T3 PL 3360864T3
Authority
PL
Poland
Prior art keywords
pyrimidine compound
pyrimidine
compound
Prior art date
Application number
PL16853686T
Other languages
English (en)
Inventor
Hidenori Kimura
Hitoshi Ban
Yoshiaki Isobe
Hitoshi Watanabe
Original Assignee
Sumitomo Dainippon Pharma Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co., Ltd. filed Critical Sumitomo Dainippon Pharma Co., Ltd.
Publication of PL3360864T3 publication Critical patent/PL3360864T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Oncology (AREA)
PL16853686T 2015-10-07 2016-10-06 Związek pirymidynowy PL3360864T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015199750 2015-10-07
EP16853686.0A EP3360864B1 (en) 2015-10-07 2016-10-06 Pyrimidine compound
PCT/JP2016/079756 WO2017061532A1 (ja) 2015-10-07 2016-10-06 ピリミジン化合物

Publications (1)

Publication Number Publication Date
PL3360864T3 true PL3360864T3 (pl) 2021-10-25

Family

ID=58487860

Family Applications (2)

Application Number Title Priority Date Filing Date
PL21164640.1T PL3868741T3 (pl) 2015-10-07 2016-10-06 Kompozycja zawierająca związek pirymidynowy i antygen pochodzący od patogenu
PL16853686T PL3360864T3 (pl) 2015-10-07 2016-10-06 Związek pirymidynowy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL21164640.1T PL3868741T3 (pl) 2015-10-07 2016-10-06 Kompozycja zawierająca związek pirymidynowy i antygen pochodzący od patogenu

Country Status (20)

Country Link
US (5) US10632192B2 (pl)
EP (2) EP3360864B1 (pl)
JP (3) JP6769976B2 (pl)
KR (1) KR102651207B1 (pl)
CN (1) CN108290845B (pl)
AU (1) AU2016334826B2 (pl)
CA (1) CA3001283C (pl)
CY (1) CY1124542T1 (pl)
DK (2) DK3868741T3 (pl)
ES (2) ES2960724T3 (pl)
FI (1) FI3868741T3 (pl)
HU (2) HUE055079T2 (pl)
MY (1) MY194902A (pl)
PH (1) PH12018500755A1 (pl)
PL (2) PL3868741T3 (pl)
PT (2) PT3360864T (pl)
RU (1) RU2759917C2 (pl)
SG (1) SG11201802832UA (pl)
TW (1) TWI718188B (pl)
WO (1) WO2017061532A1 (pl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE055079T2 (hu) * 2015-10-07 2021-10-28 Sumitomo Dainippon Pharma Co Ltd Pirimidin vegyületek
KR20230010826A (ko) 2016-10-14 2023-01-19 프리시젼 바이오사이언시스 인코포레이티드 B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제
PT3554474T (pt) * 2016-12-16 2024-02-12 Baxter Healthcare Sa Composições de micafungina
PL3603619T3 (pl) * 2017-03-29 2025-11-17 Sumitomo Pharma Co., Ltd. Preparat adjuwantu szczepionkowego
JP7037667B2 (ja) 2017-12-20 2022-03-16 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. Stingアダプタータンパク質を活性化するホスホン酸結合を有する3’3’環状ジヌクレオチド
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ, インコーポレイテッド Hbv複製阻害剤としての置換ピロリジン化合物
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2,2,─環二核苷酸
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
AU2019311965B2 (en) 2018-07-23 2026-02-19 Japan Institute For Health Security Composition containing influenza vaccine
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
EP4371987B9 (en) 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
FI3903810T3 (fi) 2018-12-26 2026-03-25 Sumitomo Pharma Co Ltd Rokoteadjuvanttia sisältävä valmiste
WO2020178769A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
CN113574063B (zh) 2019-03-07 2025-03-18 捷克共和国有机化学与生物化学研究所 3’3’-环二核苷酸及其前药
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
KR102921677B1 (ko) * 2019-04-05 2026-02-02 스미토모 파마 가부시키가이샤 수용성 보조제
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
US20220296619A1 (en) 2019-08-19 2022-09-22 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
HRP20241379T1 (hr) 2019-09-30 2024-12-20 Gilead Sciences, Inc. Cjepiva za hbv i postupci za liječenje hbv
US12410418B2 (en) 2019-12-06 2025-09-09 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
KR102987126B1 (ko) 2020-03-20 2026-07-07 길리애드 사이언시즈, 인코포레이티드 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법
CN115666632A (zh) * 2020-03-27 2023-01-31 帕斯公司 疟疾传播阻断疫苗
US20240269142A1 (en) 2021-05-13 2024-08-15 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
JP7651018B2 (ja) 2021-06-23 2025-03-25 ギリアード サイエンシーズ, インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
TW202506187A (zh) * 2023-04-12 2025-02-16 日商住友製藥股份有限公司 葡聚糖與tlr7促效劑之複合體
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
TW202608468A (zh) 2024-05-13 2026-03-01 美商基利科學股份有限公司 組合療法
US20250345390A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
ES2221414T3 (es) 1998-08-27 2004-12-16 Sumitomo Pharmaceuticals Company, Limited Derivados de pirimidina.
EP1617872A4 (en) 2003-04-10 2011-09-07 3M Innovative Properties Co METHOD AND COMPOSITIONS FOR IMPROVING THE IMMUNE RESPONSE
CA2535338C (en) 2003-08-14 2013-05-28 3M Innovative Properties Company Substituted 1h-imidazo[4,5-c]pyridin-4-amines,1h-imidazo[4,5-c]quinolin -4-amines and 1h-imidazo[4,5-c]naphthyridin-4-amines as immune response modifiers
PE20091236A1 (es) * 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
FR2924024B1 (fr) 2007-11-27 2012-08-17 Centre Nat Rech Scient Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse
PT2341933T (pt) 2008-10-24 2018-02-13 Glaxosmithkline Biologicals Sa Derivados de imidazoquinolina lipidados
FR2937549B1 (fr) * 2008-10-29 2011-04-01 Centre Nat Rech Scient Nanoparticules de derives beta-lactamine
KR20110117705A (ko) 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
JP5206513B2 (ja) 2009-03-12 2013-06-12 オムロンヘルスケア株式会社 機能追加モジュール
AU2010250923A1 (en) * 2009-05-21 2011-11-17 Astrazeneca Ab Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
US9044481B2 (en) 2009-08-07 2015-06-02 Glaxosmithkline Biologicals S.A. Lipidated oxoadenine derivatives
EP2563366A4 (en) 2010-04-30 2013-11-20 Univ California USE OF PHOSPHOLIPID CONJUGATES FROM SYNTHETIC TLR7 AGONISTS
DK2606047T3 (en) 2010-08-17 2017-03-27 3M Innovative Properties Co COMPOSITIONS AND FORMULATIONS WITH LIPIDIZED IMMUNE RESPONSE-MODIFIING COMPOUND AND PROCEDURES THEREOF
WO2012067268A1 (en) * 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Cyclic amide compounds and their use in the treatment of disease
WO2012066335A1 (en) * 2010-11-19 2012-05-24 Astrazeneca Ab Phenol compounds als toll -like receptor 7 agonists
WO2012067269A1 (en) * 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Aminoalkoxyphenyl compounds and their use in the treatment of disease
WO2012066336A1 (en) * 2010-11-19 2012-05-24 Astrazeneca Ab Benzylamine compounds as toll -like receptor 7 agonists
BR112014006643A2 (pt) * 2011-09-20 2017-04-04 Hoffmann La Roche compostos de imidazopiridina, composições e métodos de uso dos mesmos
CA2871589C (en) * 2012-05-18 2020-12-22 Seiji Hori Pyrimidine carboxylic acid derivatives and their use as tlr7 agonists
HUE055079T2 (hu) * 2015-10-07 2021-10-28 Sumitomo Dainippon Pharma Co Ltd Pirimidin vegyületek

Also Published As

Publication number Publication date
HUE055079T2 (hu) 2021-10-28
PH12018500755A1 (en) 2018-10-15
ES2870679T3 (es) 2021-10-27
US20260053911A1 (en) 2026-02-26
MY194902A (en) 2022-12-22
RU2018116351A3 (pl) 2020-02-25
JP7195398B2 (ja) 2022-12-23
TWI718188B (zh) 2021-02-11
CA3001283A1 (en) 2017-04-13
ES2960724T3 (es) 2024-03-06
PT3868741T (pt) 2023-10-19
CA3001283C (en) 2023-10-10
US11266738B2 (en) 2022-03-08
US20180280499A1 (en) 2018-10-04
PL3868741T3 (pl) 2024-01-29
CN108290845B (zh) 2021-08-03
DK3868741T3 (da) 2023-11-06
KR102651207B1 (ko) 2024-03-25
SG11201802832UA (en) 2018-05-30
US20240245766A1 (en) 2024-07-25
US20220226468A1 (en) 2022-07-21
EP3868741B1 (en) 2023-08-30
WO2017061532A1 (ja) 2017-04-13
CY1124542T1 (el) 2022-07-22
AU2016334826A1 (en) 2018-05-10
KR20180056774A (ko) 2018-05-29
US20210008197A1 (en) 2021-01-14
RU2759917C2 (ru) 2021-11-18
HK1255921A1 (en) 2019-09-06
AU2016334826B2 (en) 2020-08-27
RU2018116351A (ru) 2019-11-07
EP3360864B1 (en) 2021-04-28
EP3360864A4 (en) 2019-05-29
EP3360864A1 (en) 2018-08-15
JPWO2017061532A1 (ja) 2018-08-02
JP2021001210A (ja) 2021-01-07
FI3868741T3 (fi) 2023-10-02
TW201718518A (zh) 2017-06-01
DK3360864T3 (da) 2021-06-14
US12440560B2 (en) 2025-10-14
CN108290845A (zh) 2018-07-17
PT3360864T (pt) 2021-06-02
US11911466B2 (en) 2024-02-27
EP3868741A1 (en) 2021-08-25
JP6769976B2 (ja) 2020-10-14
US10632192B2 (en) 2020-04-28
HUE064322T2 (hu) 2024-03-28
JP2022010266A (ja) 2022-01-14

Similar Documents

Publication Publication Date Title
FIC20230006I1 (fi) Vutrisiraani
DK3360864T3 (da) Pyrimidinforbindelse
EP3578560A4 (en) QUINAZOLINE COMPOUND
DK3627029T3 (da) Manipulationssikret låg
EP3360001A4 (en) HEAD-MOUNTED DISPLAY DEVICE
IL265166B (en) Anti-influenza virus pyrimidine derivatives
PT3298027T (pt) Compostos depsipéptidos antelmínticos
EP3337164A4 (en) HEAD-MOUNTED DISPLAY
KR20180084876A (ko) 내플라즈마성 부재
EP3435660A4 (en) HEAD-MOUNTED DISPLAY
EP3564216A4 (en) PYRIMIDINE DERIVATIVE
EP3372588A4 (en) pyrimidine
SMT202200173T1 (it) Composti
LT3362444T (lt) Junginiai
DK3597189T3 (da) Krystallinske forbindelser
DK3347403T3 (da) Polyalkoxyfedtforbindelse
DE112015006486A5 (de) Inkubationsrinne
BR112018001062A2 (pt) compostos inovadores
EP3346592A4 (en) Rotating machine
EP3372589A4 (en) pyrimidine derivative
LT3331885T (lt) Junginiai
DE102015206660A8 (de) Plattenaufteilanlage
EP3454107A4 (en) HEAD MOUNTED DISPLAY
DE112015005905A5 (de) Gurtschlossbringer
DK3630729T3 (da) Pyrimidinforbindelse